Arvinas, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 7.86 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 513.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Details
| Name | Arvinas, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 246 |
| Founded | 2015 |
| Ipo Date | 2018-09-27 |
| Ceo | Randy Teel |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US04335A1051 |
| Cusip | 04335A105 |
| Cik | 0001655759 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Randy Teel Ph.D. | Chief Executive Officer, President and Director |
| Andrew R. Saik | Chief Financial Officer and Treasurer |
| Angela M. Cacace Ph.D. | Chief Scientific Officer |
| David K. Loomis M.B.A. | Vice President and Chief Accounting Officer |
| Jeff Boyle | Vice President of Investor Relations |
| Jared M. Freedberg J.D. | General Counsel and Corporate Secretary |
| Steve Weiss | Senior Vice President and Chief Human Resources Officer |
| Kelly Page | Senior Vice President and Global Head of Oncology Strategy and Program Leadership |
Contact
| Address | 5 Science Park, 395 Winchester Avenue, New Haven, Connecticut 06511, United States |
| Phone | 203 535 1456 |
| Website | https://www.arvinas.com |